“Vertex’s willingness to drop VX-961 based on those variables reflects a belief that safety and efficacy are “table stakes--支柱” in pain. To succeed, Vertex is looking for “a molecule with the perfect PK” for the indication. That search is underpinned by an understanding of how pain...
3、https://www.orion.fi/en/Orion-group/media/press-releases/2022/orion-enters-into-exclusive-agreement-with-jemincare-for-novel-non-opioid-drug-candidate-for-the-treatment-of-pain/?epieditmode=true. 4、https://news.vrtx.com/news-r...
Jones J, Correll DJ, Lechner SM, et al. Selective Inhibition of Na1.8 with VX-548 for Acute Pain.N Engl J Med. doi:10.1056/NEJMoa2209870. 『梧桐医学』是由麻醉学(包含疼痛方向)本科、硕士、博士、博后以及刚工作的年轻医生组建的学习型...
VX-548 is an oral, selective NaV1.8 inhibitor that is highly selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that plays a critical role in pain signaling in the peripheral nervous system. NaV1.8 is a genetically validated target for the...
for the design of low MW blockers for the treatment of chronic pain. The NAV1.8 channel is highly expressed by small primary sensory neuronsand is closely related to the occurrence and development of various types of pain, such as inflammatory pain, neuropathic pain, and inflammatory pain. ...
VX-548 is an oral, selective NaV1.8 inhibitor that is highly selective for NaV1.8 relative to other NaV channels. NaV1.8 is a voltage-gated sodium channel that plays a critical role in pain signaling in the peripheral nervous system. NaV1.8 is a genetically validated target for the ...
The transient receptor potential (TRP) family of ion channels has been the subject of intensive drug discovery efforts due to their critical role in the development and progression of pain, itch, and respiratory conditions. Read More ( 10 min) OPEN ACCESS MODALITIES & TECHNOLOGY PRIMERS 2024 ...
This is likely related to a failure in proving the efficacy of alternative analgesics in clinical trials, despite strong evidence supporting the potential for effective analgesia through in vitro studies. While NaV1.7 and NaV1.8 channels have shown to be key components of pain perception, studies ...
METHODSAfter establishing the selectivity of VX-548 forNaV1.8inhibition in vitro, we conducted two phase 2 trials involving participants with acute pain after abdominoplasty or bunionectomy. In the abdominoplasty trial, participants were randomly assigned in a 1:1:1:1 ratio to receive one of th...
Chief Executive Officer and President ofVertex. “With FDA Breakthrough and Fast Track Designations in hand, we are working with urgency to file the New Drug Application for VX-548 and bring this non-opioid medicine to the millions of patients who suffer from acute pain each year in the U...